Publication:
miR-222 exerts negative regulation on insulin signaling pathway in 3T3-L1 adipocytes

dc.contributor.authorBibiloni, Pedro
dc.contributor.authorPomar, Catalina Amadora
dc.contributor.authorPalou, Andreu
dc.contributor.authorSánchez, Juana
dc.contributor.authorSerra, Francisca
dc.date.accessioned2024-10-04T13:46:19Z
dc.date.available2024-10-04T13:46:19Z
dc.date.issued2022-10-30
dc.description.abstractIncreased miR-222 levels are associated with metabolic syndrome, insulin resistance, and diabetes. Moreover, rats fed an obesogenic diet during lactation have higher miR-222 content in breast milk and the offspring display greater body fat mass and impaired insulin sensitivity in adulthood. In order to investigate the molecular mechanisms involved and to dissect the specific effects of miR-222 on adipocytes, transfection with a mimic or an inhibitor of miR-222 has been conducted on 3T3-L1 preadipocytes. 3T3-L1 cells were transfected with either a mimic or an inhibitor of miR-222 and collected after 2 days (preadipocytes) or 8 days (mature adipocytes) for transcriptomic analysis. Results showed a relevant impact on pathways associated with insulin signaling, lipid metabolism and adipogenesis. Outcomes in key genes and proteins were further analyzed with quantitative reverse transcription polymerase chain reaction and Western Blotting, respectively, which displayed a general inhibition in important effectors of the identified routes under miR-222 mimic treatment in preadipocytes. Although to a lesser extent, this overall signature was maintained in differentiated adipocytes. Altogether, miR-222 exerts a direct effect in metabolic pathways of 3T3-L1 adipocytes that are relevant to adipocyte function, limiting adipogenesis and insulin signaling pathways, offering a mechanistic explanation for its reported association with metabolic diseases.en
dc.description.sponsorshipThis research was supported by Project PI20/00417,funded by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional Una Manera de hacer Europa.The Research Group Nutrigenomics, Bio-markers and Risk Evaluation receives financial support from Instituto de Salud Carlos III and Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn). PB has a predoctoral research contract (FPU20/06023-Ministerio de Universidades).es_ES
dc.identifier.citationBibiloni P, Pomar CA, Palou A, Sánchez J, Serra F. miR-222 exerts negative regulation on insulin signaling pathway in 3T3-L1 adipocytes. BioFactors. 2022 Oct 30.en
dc.identifier.doi10.1002/biof.1914
dc.identifier.e-issn1872-8081es_ES
dc.identifier.journalBioFactors (Oxford, England)es_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/18601
dc.identifier.pubmedID36310379es_ES
dc.identifier.puiL2019866790
dc.identifier.scopus2-s2.0-85141178778
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23480
dc.identifier.wos876163000001
dc.language.isoengen
dc.publisherWiley
dc.relation.publisherversionhttps://doi.org/10.1002/biof.1914en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titlemiR-222 exerts negative regulation on insulin signaling pathway in 3T3-L1 adipocytesen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files